Mid-sized clinical contract research organisation (CRO), TFS International, has entered into an agreement with the Pharma Intelligence division of Informa for their global research and development (R&D) platform — Citeline
strategic partnership
“At TFS we are already proud of the strategic and operational services that we provide our biotechnology and pharma clients,” said Dr Bassem Saleh, TFS chief medical officer. “This agreement with Citeline will take us to the next level and provide the strategy and operational team’s access to global, R&D intelligence platforms on a par with the largest CRO organisations.”
Through this agreement TFS will be able to maximise data analytics to create effective study strategies, perform comprehensive endpoint analysis, gain access to country specific enrolment benchmarks and patient data, access target locations and identify and prioritise qualified investigators and sites from the Citeline database, amongst other things.
“Citeline is the industry’s most comprehensive, reliable and current global R&D intelligence suite of solutions,” concluded Saleh. “Along with my IT colleagues, we are always looking for the industry-leading technologies to drive TFS forward, and with Citeline we are demonstrating exactly that.”
“We are very excited about our cooperation with Citeline,” added chief executive officer, János Filakovský. “We will continue to invest in industry leading technologies, and in our people to provide innovative, data-driven productive solutions to our global customers.”